94 TWENTYFOURSEVENBIOPHARMA Issue 1 / March 2026 DCAT ROUNDTABLE Are customers prioritising cost control over resilience and innovation, or are you seeing a more balanced approach emerge? The current funding environment for biotech companies has reinforced the need for strong cost discipline. At the same time, recent supply chain disruptions have highlighted a critical lesson for the industry: the lowest-cost option does not always provide the greatest reliability. Today, many organizations are seeking to strike a more balanced approach, weighing: - Cost efficiency - Supply reliability - Long-term scalability As a result, outsourcing discussions are shifting from a narrow focus on price toward a broader evaluation of overall supply chain value. Where do you see the most meaningful growth opportunities in the next 12–18 months - geographically or technologically? Looking ahead, several segments of the outsourcing market continue to demonstrate strong momentum. Complex therapies and combination products including autoinjectors and other device-based drug delivery systems are expanding rapidly and require specialized expertise in both packaging and device integration. In addition, we are seeing robust activity among mid-sized and emerging biotech companies preparing assets for late-stage clinical trials or initial commercial launches. From a geographic perspective, North America and Europe remain the most active outsourcing markets, particularly for programs where regulatory expertise and commercial readiness are key priorities. What is the biggest misconception pharma companies currently have about the CDMO/API supply environment? One persistent misconception within the pharmaceutical industry is that CDMO capacity remains universally constrained. In reality, the situation has become more nuanced. Over the past several years, the industry invested significantly in expanding manufacturing and packaging capacity. While certain specialized technologies remain constrained, many areas now have greater availability than during the height of the pandemic-driven demand surge. As a result, the primary challenge today is not simply securing capacity. Instead, companies are increasingly focused on identifying partners with the appropriate expertise, flexibility, and development capabilities to support their specific programs. At Tjoapack, we see this dynamic firsthand. More organizations are seeking partners who can provide both early-stage flexibility and the operational readiness required for commercialization - particularly for specialized packaging and complex drug-device combination products. In many cases, the companies achieving the strongest outcomes are those that engage outsourcing partners earlier in the development process. NOT JUST A STORY: AN EXTRA-ORDINARY EXPERIENCE
RkJQdWJsaXNoZXIy MjY2OTA4MA==